Indo Borax & Ch. Q1 FY27 Earnings Call — Analysis (NSE: INDOBORAX)
Indo Borax reported strong Q1 FY27 revenue growth of 31% YoY with EBITDA margins reaching 28.1%, while outlining a ₹400+ Cr funding framework for its majority acquisition of Kronox Lab Sciences.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Operating Revenue ₹70.36 Cr ( +31.34% YoY ) . New guidance — FY27 fy27 revenue and ebitda margin ₹250 Cr to ₹260 Cr . New story: Kronox Acquisition and Synergy Realization .
Results
Revenue ₹70.36 Cr (+31.3% YoY); EBITDA margin 28.1% (+531bps); PAT ₹16.25 Cr (+59.3% YoY).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Operating Revenue | ₹70.36 Cr | +31.34% | yoy · Q1FY27 · Q1FY26 ₹53.57 Cr |
| EBITDA | ₹19.80 Cr | +62.16% | yoy · Q1FY27 · Q1FY26 ₹12.21 Cr |
| EBITDA Margin | 28.10% | +531bps | yoy · Q1FY27 · vs 22.79% in Q1FY26 |
| Net Profit | ₹16.25 Cr | +59.31% | yoy · Q1FY27 · Q1FY26 ₹10.20 Cr |
| PAT Margin | 22.30% | +430bps | yoy · Q1FY27 · Q1FY26 18.00% |
| EPS | ₹5.07 | +59.43% | yoy · Q1FY27 · Q1FY26 ₹3.18 |
Guidance
Full-year FY27 revenue guided at ₹250 Cr to ₹260 Cr with ~20% EBITDA margin.
What management committed to
- While the full year guidance... we will be closing at about Rs. 250 crores to Rs. 260 crores of revenue with a 20% EBITDA margin [in FY27]. — Rs. 250 crores to Rs. 260 crores, FY27
- This year, my official target plan is 1,500 tons for [DOT]... and we are confident that this year we definitely will be closing at about 1,500 tons of this product. — 1,500 tons, FY27
- We are looking forward to about a Rs. 50 crores of Capex over the next two to three years... Boron oxide [Rs. 20 crores] and Boric acid [Rs. 20 to Rs. 25 crores]. — Rs. 50 crores, FY29
- This year, we look forward to increase [Boric acid production] further, to about 18,000 tons. — 18,000 tons, FY27
- [Indo Borax is] currently in the process of selling two non-core assets that we have in terms of commercial office spaces... in the city of Mumbai for a total consideration of about Rs 48 Crore. — Rs 48 Crore, FY27
- It would be Financial Year '29, we will start seeing the benefits [from Kronox Dahej capex]. And I think Financial Year '30 and '31 would be the 100% impact on the full capex. — FY29
Key themes
Strategic specialty chemical acquisition and capacity expansion
How the narrative shifted
- Kronox Acquisition and Synergy Realization: Management frames the Kronox acquisition as a strategic platform expansion to access global markets and 185 specialty chemical products while leveraging Indo Borax's operational and supply chain strength.
- Boron Portfolio Optimization and Forward Integration: Company is shifting mix towards higher-margin forward-integrated DOT and IP-grade Boric acid for pharma/personal care while expanding base technical grade capacity.
- Margin Normalization and Input Cost Dynamics: Management highlights that exceptional Q1 margins (28%) will normalize towards 20% for the full year due to raw material inflation lag and seasonal monsoon softness in Q2.
- Acquisition Funding and Promoter Leverage Architecture: Management outlines a ring-fenced financing structure using Indo Borax internal cash, non-core asset sales, term loans, and promoter capital to fund the ₹400+ Cr transaction.
Operational commentary
- Board approved acquisition of 64.26% stake in Kronox Lab Sciences for ~₹250 Cr; Indo Borax to lead integration and cross-sell Kronox's 185 specialty chemical products across global distribution channels.
- Planned capex of ~₹50 Cr over next 2-3 years at Indo Borax: ₹20 Cr for Boron Oxide and ₹20-25 Cr for Boric Acid capacity expansion.
- Targeting 1,500 tonnes of Disodium Octaborate Tetrahydrate (DOT) production in FY27 (vs 900 tonnes in FY26), scaling up to 9% of total revenue.
- Practical boric acid capacity utilization expected to reach 18,000 tonnes in FY27 against 20,000 tonnes nameplate capacity (up from 15,917 tonnes in FY26).
- Kronox Dahej capex planned at ~₹110 Cr (Phase 1 ₹55-60 Cr funded from Kronox's ₹80 Cr cash reserves), targeted to go live in FY29 with full revenue potential of 3-3.5x by FY30-31.
- Scheme of amalgamation approved for wholly-owned subsidiary Indo Borax Infrastructure Pvt Ltd with parent company.
Analyst Q&A
Q. What is the funding structure for the Kronox acquisition and the associated open offer?
Harsh Malhotra detailed funding sources: ₹134-135 Cr from internal accruals/liquid investments, ~₹48 Cr from the ongoing sale of two Mumbai commercial properties, bank term loans for the remaining gap and open offer, plus ₹25 Cr promoter equity backing, creating ₹432 Cr total availability against ~₹400 Cr requirement.
Q. What is the timeline for unpledging the Indo Borax shares pledged by promoter entity Zenrock?
Management clarified that share pledge is standard collateral for acquisition financing and remains a work in progress with no specific timeline to report.
Q. What is the interest rate on the NCDs issued by the promoter group SPV Zenrock?
Harsh Malhotra declined to provide the exact coupon rate on the call, directing the analyst to contact the company secretary and compliance officer offline.
Q. Will Kronox be merged into Indo Borax to avoid a holding company discount?
Suresh Kalra stated there is no immediate plan to merge; both companies will operate as separate listed entities under a unified leadership team.
Research and educational content only. Not investment advice.